Collaboration with Arvinas Pharmaceuticals

June 25, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Arvinas (Nasdaq:ARVN), a pharmaceutical company inventing the famous proprietary PROTAC® protein degraders.

Read more >
Read more

Collaboration with ErVaccine Technologies

June 20, 2021 | BALTIMORE –  Complete Omics’ announced a collaboration with ErVaccine Technologies, a pharmaceutical company headquartered in Lyon, Rhone-Alpes, Francey, on a neoantigen validation and quantification project.

Read more >
Read more

Collaboration with Dr. Yonghong Wan from McMaster University

June 16, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Yonghong Wan’s lab at McMaster University at Hamilton Ontario Canada.

Read more >
Read more

Collaboration with Emory

June 4, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Sun Shi-yong lab in the Winship Cancer Institute of Emory University.

Read more >
Read more

Collaboration with Grünenthal

May 4, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Grünenthal, a pharmaceutical company headquartered in Aachen in Germany, on a series of clinical single-cell based proteomics projects.

Read more >
Read more

Collaboration with Frame Cancer Therapeutics

April 26, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Frame Cancer Therapeutics, an Amsterdam pharmaceutical company,  on a series of clinical proteomics projects.

Read more >
Read more

Collaboration with Ludwig Cancer Research.

April 21, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Ludwig Cancer Research Center on a series of clinical proteomics projects.

Read more >
Read more

Collaboration with Hemogenyx Pharmaceuticals.

April 15, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Hemogenyx Pharmaceuticals on a series of clinical proteomics projects.

Read more >
Read more

Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media

Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.

Read more >
Read more

Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.

Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.

Read more >
Read more
Follow by Email
Facebook
Twitter
LinkedIn